Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analog of a postulated toxic metabolite

1986 ◽  
Vol 108 (9) ◽  
pp. 2464-2466 ◽  
Author(s):  
L. M. Sayre ◽  
P. K. Arora ◽  
S. C. Feke ◽  
F. L. Urbach
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Electrochemical Characterization ◽  
Toxic Metabolite

Dementia in Parkinson's disease: characterization of transmitter deficits

2004 ◽  
Vol 31 (S 1) ◽  
Author(s):  
A Thomas ◽  
R Hilker ◽  
E Kalbe ◽  
S Weisenbach ◽  
K Herholz ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease

scholarly journals Discovery and characterization of naturally occurring potent inhibitors of catechol-O-methyltransferase from herbal medicines

RSC Advances ◽  
2021 ◽  
Vol 11 (17) ◽  
pp. 10385-10392
Author(s):  
Dong-Fang Zhao ◽  
Yu-Fan Fan ◽  
Fang-Yuan Wang ◽  
Fan-Bin Hou ◽  
Frank J. Gonzalez ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Herbal Medicines ◽  
Disease Treatment ◽  
Naturally Occurring

Discovery and characterization of natural human catechol-O-methyltransferase (hCOMT) inhibitors for Parkinson's disease treatment.

scholarly journals Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0172394 ◽  
Author(s):  
Robert Westphal ◽  
Camilla Simmons ◽  
Michel B. Mesquita ◽  
Tobias C. Wood ◽  
Steve C. R. Williams ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Network Topology ◽  
Rat Model ◽  
Resting State ◽  
Brain Network ◽  
6 Hydroxydopamine

scholarly journals Accelerating diagnosis of Parkinson’s disease through risk prediction

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
William Yuan ◽  
Brett Beaulieu-Jones ◽  
Richard Krolewski ◽  
Nathan Palmer ◽  
Christine Veyrat-Follet ◽  
...  
Keyword(s):  
Machine Learning ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subsequent Development ◽  
Time Compression ◽  
Disease Modifying Therapies ◽  
Machine Learning Approach ◽  
Diagnostic Window

Abstract Background Characterization of prediagnostic Parkinson’s Disease (PD) and early prediction of subsequent development are critical for preventive interventions, risk stratification and understanding of disease pathology. This study aims to characterize the role of the prediagnostic period in PD and, using selected features from this period as novel interception points, construct a prediction model to accelerate the diagnosis in a real-world setting. Methods We constructed two sets of machine learning models: a retrospective approach highlighting exposures up to 5 years prior to PD diagnosis, and an alternative model that prospectively predicted future PD diagnosis from all individuals at their first diagnosis of a gait or tremor disorder, these being features that appeared to represent the initiation of a differential diagnostic window. Results We found many novel features captured by the retrospective models; however, the high accuracy was primarily driven from surrogate diagnoses for PD, such as gait and tremor disorders, suggesting the presence of a distinctive differential diagnostic period when the clinician already suspected PD. The model utilizing a gait/tremor diagnosis as the interception point, achieved a validation AUC of 0.874 with potential time compression to a future PD diagnosis of more than 300 days. Comparisons of predictive diagnoses between the prospective and prediagnostic cohorts suggest the presence of distinctive trajectories of PD progression based on comorbidity profiles. Conclusions Overall, our machine learning approach allows for both guiding clinical decisions such as the initiation of neuroprotective interventions and importantly, the possibility of earlier diagnosis for clinical trials for disease modifying therapies.

scholarly journals Single Molecule FRET Characterization of Oligomers from Alpha-Synuclein Early Onset Parkinson's Disease Mutants

2014 ◽  
Vol 106 (2) ◽  
pp. 269a ◽  
Author(s):  
Laura Tosatto ◽  
Mathew H. Horrocks ◽  
Cremades Nunilo ◽  
Tim Guilliams ◽  
Mauro Dalla Serra ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Single Molecule ◽  
Early Onset ◽  
Alpha Synuclein ◽  
Single Molecule Fret ◽  
Early Onset Parkinson’S Disease

scholarly journals Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease

Cells ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 105 ◽  
Author(s):  
Maria Zella ◽  
Judith Metzdorf ◽  
Friederike Ostendorf ◽  
Fabian Maass ◽  
Siegfried Muhlack ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Glial Cell ◽  
Dopaminergic Neurons ◽  
Basic Research ◽  
Alpha Synuclein ◽  
Models Of Disease ◽  
Novel Therapeutic Strategies ◽  
Lymphocyte Populations

The etiology of Parkinson’s disease (PD) is significantly influenced by disease-causing changes in the protein alpha-Synuclein (aSyn). It can trigger and promote intracellular stress and thereby impair the function of dopaminergic neurons. However, these damage mechanisms do not only extend to neuronal cells, but also affect most glial cell populations, such as astroglia and microglia, but also T lymphocytes, which can no longer maintain the homeostatic CNS milieu because they produce neuroinflammatory responses to aSyn pathology. Through precise neuropathological examination, molecular characterization of biomaterials, and the use of PET technology, it has been clearly demonstrated that neuroinflammation is involved in human PD. In this review, we provide an in-depth overview of the pathomechanisms that aSyn elicits in models of disease and focus on the affected glial cell and lymphocyte populations and their interaction with pathogenic aSyn species. The interplay between aSyn and glial cells is analyzed both in the basic research setting and in the context of human neuropathology. Ultimately, a strong rationale builds up to therapeutically reduce the burden of pathological aSyn in the CNS. The current antibody-based approaches to lower the amount of aSyn and thereby alleviate neuroinflammatory responses is finally discussed as novel therapeutic strategies for PD.

scholarly journals The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson’s Disease

2011 ◽  
Vol 2 (12) ◽  
pp. 730-742 ◽  
Author(s):  
Zixiu Xiang ◽  
Analisa D. Thompson ◽  
John T. Brogan ◽  
Michael L. Schulte ◽  
Bruce J. Melancon ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Calcium Channel ◽  
Rodent Model
Sign in / Sign up

Export Citation Format

Share Document